DS
CURX

DRW Securities’s Curanex Pharmaceuticals CURX Stock Holding History

DRW Securities’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-71,553
Closed -$23.7K – 1841
2025
Q4 		$23.7K Buy
+71,553
New +$39.4K ﹤0.01% 1159

Other funds holding CURX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DRW Securities's CURX Position: Q1 2026 in Review

DRW Securities sold out of Curanex Pharmaceuticals (CURX) in Q1 2026, closing a stake of 71,553 shares — an estimated $23.7K sold.

DRW Securities first reported a position in CURX in Q4 2025 and held it in 1 quarter. The position peaked at $23.7K in Q4 2025. 8 funds tracked by Wall St. Rank hold CURX as of Q1 2026.

  • DRW Securities reported no remaining Curanex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 71,553 Curanex Pharmaceuticals shares in Q1 2026, an estimated $23.7K.
  • DRW Securities first reported a position in Curanex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • DRW Securities's Curanex Pharmaceuticals position peaked at $23.7K in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.